The prognosis for patients with rheumatoid arthritis or spondyloarthritides has improved dramatically due to earlier diagnosis, recognition of the need to treat early with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), alone or in combinations, the establishment of treatment targets, and the development of biological DMARDs (bDMARDs). Many patients are now able to achieve clinical remission or low disease activity with therapy, and reduce or eliminate systemic corticosteroid use. Guidelines recommend methotrexate as a first-line agent for the initial treatment of rheumatoid arthritis; however, a majority of patients will require a change of csDMARD or step up to combination therapy with the addition of another csDMARD or a bDMARD. However, treatment failure is common and switching to a different therapy may be required. The large number of available treatment options, combined with a lack of comparative data, makes the choice of a new therapy complex and often not evidence based. We summarize and discuss evidence to inform treatment decisions in patients who require a change in therapy, including baseline factors that may predict response to therapy.

Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides / Govoni, Marcello; Bortoluzzi, Alessandra; Lo Monaco, Andrea; Adami, Silvano; Addimanda, Olga; Caimmi, Cristian; De Vita, Salvatore; Ferri, Clodoveo; Manfredi, Andreina Teresa; Orsolini, Giovanni; Possemato, Niccolò; Quartuccio, Luca; Salvarani, Carlo; Zabotti, Alen; Rossini, Maurizio. - In: ADVANCES IN THERAPY. - ISSN 0741-238X. - STAMPA. - 31:8(2014), pp. 780-802. [10.1007/s12325-014-0142-8]

Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides

FERRI, Clodoveo;MANFREDI, Andreina Teresa;SALVARANI, CARLO;
2014

Abstract

The prognosis for patients with rheumatoid arthritis or spondyloarthritides has improved dramatically due to earlier diagnosis, recognition of the need to treat early with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), alone or in combinations, the establishment of treatment targets, and the development of biological DMARDs (bDMARDs). Many patients are now able to achieve clinical remission or low disease activity with therapy, and reduce or eliminate systemic corticosteroid use. Guidelines recommend methotrexate as a first-line agent for the initial treatment of rheumatoid arthritis; however, a majority of patients will require a change of csDMARD or step up to combination therapy with the addition of another csDMARD or a bDMARD. However, treatment failure is common and switching to a different therapy may be required. The large number of available treatment options, combined with a lack of comparative data, makes the choice of a new therapy complex and often not evidence based. We summarize and discuss evidence to inform treatment decisions in patients who require a change in therapy, including baseline factors that may predict response to therapy.
2014
31
8
780
802
Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides / Govoni, Marcello; Bortoluzzi, Alessandra; Lo Monaco, Andrea; Adami, Silvano; Addimanda, Olga; Caimmi, Cristian; De Vita, Salvatore; Ferri, Clodoveo; Manfredi, Andreina Teresa; Orsolini, Giovanni; Possemato, Niccolò; Quartuccio, Luca; Salvarani, Carlo; Zabotti, Alen; Rossini, Maurizio. - In: ADVANCES IN THERAPY. - ISSN 0741-238X. - STAMPA. - 31:8(2014), pp. 780-802. [10.1007/s12325-014-0142-8]
Govoni, Marcello; Bortoluzzi, Alessandra; Lo Monaco, Andrea; Adami, Silvano; Addimanda, Olga; Caimmi, Cristian; De Vita, Salvatore; Ferri, Clodoveo; M...espandi
File in questo prodotto:
File Dimensione Formato  
ther_govoni.pdf

Solo gestori archivio

Descrizione: articolo finale
Tipologia: Versione pubblicata dall'editore
Dimensione 581.95 kB
Formato Adobe PDF
581.95 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1063908
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact